Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes ( 2019; 34:382-9, Han Na Jang et al.)

Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes ( 2019; 34:382-9, Han Na Jang et al.)

Bibliographic Details
Main Author:	Sang Youl Rhee
Format:	Article
Language:	English
Published:	Korean Endocrine Society 2020-03-01
Series:	Endocrinology and Metabolism
Online Access:	https://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-35-192.pdf

Similar Items

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
by: Han Na Jang, et al.
Published: (2019-12-01)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01)

Degludec insulin: A novel basal insulin
by: Sanjay Kalra, et al.
Published: (2011-01-01)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
by: Shinje Moon, et al.
Published: (2021-09-01)

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
by: Wang F, et al.
Published: (2012-07-01)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
by: Sami N. Nasrallah, et al.
Published: (2012-04-01)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
by: Sami N. Nasrallah, et al.
Published: (2012-01-01)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
by: Kyu Yong Cho, et al.
Published: (2020-08-01)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
by: Qiong Luo, et al.
Published: (2022-10-01)

Insulin degludec
by: Vishakha V Jain, et al.
Published: (2013-01-01)

Practical guide in using insulin degludec/insulin aspart: A multidisciplinary approach in Malaysia
by: Siew Pheng Chan, et al.
Published: (2023-05-01)

The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
by: M. V. Shestakova, et al.
Published: (2021-07-01)

Insulin degludec aspart: One-year real world experience
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Insulin degludec: overview of a novel ultra long-acting basal insulin.
by: Gough, S, et al.
Published: (2013)

Insulin degludec: Overview of a novel ultra long-acting basal insulin
by: Gough, S, et al.
Published: (2013)

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial.
by: Ajay Kumar, et al.
Published: (2016-01-01)

Comparing time to intensification between insulin degludec/insulin aspart and insulin glargine: A single-center experience from India
by: Rajiv Kovil
Published: (2022-01-01)

Insulin degludec: A novel ultra-acting basal insulin: Potential usefulness in hospitalized patients
by: Sukhminder Jit Singh Bajwa, et al.
Published: (2015-01-01)

The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
by: Sarah J. Glastras, et al.
Published: (2020-04-01)

Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
by: Tevfik Demir, et al.
Published: (2021-03-01)

Low fasting glucose‐to‐estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes
by: Han Na Jang, et al.
Published: (2022-01-01)

Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience
by: Hatice Oner, et al.
Published: (2022-07-01)

Pediatric diabetes: Potential for insulin degludec
by: Sanjay Kalra, et al.
Published: (2014-01-01)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
by: Hongzhong Liu, et al.
Published: (2022-04-01)

Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-07-01)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
by: Aye MM, et al.
Published: (2014-04-01)

Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
by: Marina Vladimirovna Shestakova, et al.
Published: (2015-12-01)

Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Yunjiao Yang, et al.
Published: (2022-05-01)

Patient reported attitude, practice, satisfaction, and quality of life on insulin degludec/insulin aspart: A single-center survey from India in adult with diabetes
by: Rajiv Kovil
Published: (2022-01-01)

Efficacy and safety of ultra-long-acting insulin degludec
by: Ammar Wakil, et al.
Published: (2012-04-01)

Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements
by: Scott M. Pearson, et al.
Published: (2018-04-01)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
by: Mizuho Yamabe
Published: (2019-11-01)

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
by: Meneghini, L, et al.
Published: (2013)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
by: Dippel, Franz-Werner, et al.
Published: (2010-01-01)

Efficacy and tolerance of insulin degludec administered once/day in a pattern unique flexible compared to insulin glargine once daily at a fixed time in patients with type 2 diabetes (T2D)
by: Huet, D, et al.
Published: (2012)

Insulin Glargine and Insulin Aspart Overdose With Pharmacokinetic Analysis
by: Christian C.K. Kim, MD, et al.
Published: (2016-01-01)

Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes
by: Atkin, S, et al.
Published: (2011)

Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes
by: Junko Oya, et al.
Published: (2021-11-01)

Comparison of the Impact of Insulin Degludec U100 and Insulin Glargine U300 on Glycemic Variability and Oxidative Stress in Insulin-Naive Patients With Type 2 Diabetes Mellitus: Pilot Study for a Randomized Trial
by: Pavle Vrebalov Cindro, et al.
Published: (2022-07-01)